Viking Therapeutics, Inc. (VKTX): Net Income
-$359.64M
Year ended 2025-12-31
-$534.80M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$359.64M | n/m | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | -$109.96M | n/m | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | -$85.89M | n/m | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | -$68.87M | n/m | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | -$54.99M | n/m | 2024-02-07, From 2021-01-01 |
| 2020-12-31 | -$39.49M | n/m | 2022-02-09, From 2020-01-01 |
| 2019-12-31 | -$25.78M | n/m | 2021-02-17, From 2019-01-01 |
| 2018-12-31 | -$22.06M | n/m | 2020-02-26, From 2018-01-01 |
| 2017-12-31 | -$20.58M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$14.73M | n/m | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | -$23.40M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$21.88M | n/a | 2016-03-08, From 2014-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | -$359.64M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$569.0K | n/m |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $20.45M | +159.1% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
Compare VKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗